THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Thursday, March 16, 2023
Greece will likely resume its first medical cannabis production facility with legal access, post 6 years after the passing of the amendment.
FREMONT, CA: Greece’s very first medical cannabis production facility is likely under development, due to which patient advocates have increasingly relied on illicit markets to access medical cannabis in the desired period. Wherein, legal access to cannabis medicines will come into effect in 2023, six years after its amendment, opening up seamless medical facilities for convalescents in the arena. The operations have already begun with a vertically integrated production unit, located on private land of 56,000 square metres in Korinthos, with a plausible investment of nearly 40 million euros.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Officials in the country and patient organisations are extending their support for the facility following the announcement that the medical cannabis market will resume in 2023. Leaders in Greece stated that the approach is undeniably a historic achievement for Europe in terms of delivering pharmaceutical cannabis products to Greek patients. In addition to opening up a new opportunity in Greece, opening up the first medical cannabis arena will likely regulate the export of cannabis medicine throughout Europe, spearheaded by the cannabis industry and several other relative horizons to work on medical cannabis.
The framework is reprehensible for almost various arenas in the cannabis medicine space, where monitoring the development of medical cannabis for investors and patients enables easy access to these medicines on an efficient note. Announced in 2017 to effectuate medical cannabis usage and its legalisation, the pact was an aftereffect of a campaign imposed by mothers of children suffering severe epilepsy. As a result, cannabis has emerged as a legally prescribed drug and has been approved for usage in three critical conditions—multiple sclerosis (MS), chronic pain, and cancer-related cachexia.
Furthermore, extensive laws were prescribed in the following annuals, underlining the licensing requirements for organisations, aiming to produce medicinal cannabis products in Greece. However, progress in implementing cannabis medicine in Greece required an increased pace, as patients often faced complications and protracted hindrances in obtaining cannabis-based drugs like Epiddyolex and Sativex via individual import requests. A patient in Greece has successfully received Sativex for treatment after a post-18-month battle, marking the first use of medical cannabis in Greece.
An imposed ban on medical cannabis access in Greece has likely stimulated the growth of obtaining medicine through illicit markets—growing their own and illegally importing oils. People in Greece are quite familiar with cannabinoids (CBD), especially their wide availability in retail stores and over-the-counter pharmacies. Thus, cannabinoids encompass a healthy legal market in Greece.
More in News